| Overview |
| bs-3509R-Cy7 |
| CTDSPL Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Dog, Cow, Pig, Chicken, Rabbit |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CTDSPL |
| 145-250/276 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10217 |
| O15194 |
| Nucleus |
| PSR1; SCP3; HYA22; RBSP3; C3orf8; CTD small phosphatase-like protein; CTDSP-like; Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 3; NIF-like protein; Nuclear LIM interactor-interacting factor 1; NLI-interacting factor 1; Protein YA22; Small C-terminal domain phosphatase 3; Small CTD phosphatase 3; CTDSPL; NIF1; NIFL; YA22 |
| Recruited by REST to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells (By similarity). Preferentially catalyzes the dephosphorylation of 'Ser-5' within the tandem 7 residue repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit POLR2A. Negatively regulates RNA polymerase II transcription, possibly by controlling the transition from initiation/capping to processive transcript elongation. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz